Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Risperidone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 14/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 13/20 | 1.00 |
| ▸ | HTR2C known ✓ | P28335 | 4/20 | 1.00 |
| ▸ | HTR1A | P08908 | 5/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
| ▸ | HRH1 | P35367 | 3/20 | 1.00 |
| ▸ | DRD3 | P35462 | 3/20 | 1.00 |
| ▸ | ACHE | P22303 | 3/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | DRD4 | P21917 | 2/20 | 1.00 |
| ▸ | DRD5 | P21918 | 2/20 | 1.00 |
| ▸ | HTR1D | P28221 | 2/20 | 1.00 |
| ▸ | HTR1B | P28222 | 2/20 | 1.00 |
| ▸ | HTR7 | P34969 | 2/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Risperidone SCHEMBL16965766 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR1AKCNH2HTR2C | |
| Risperidone SCHEMBL29392548 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR1AKCNH2HTR2C | |
| Risperidone SCHEMBL27911 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR1AKCNH2HTR2C | |
| Risperidone SCHEMBL5777424 | 0.99 | DRD2 (0.98) | DRD2HTR2AHTR1AKCNH2HTR2C | |
| Risperidone SCHEMBL20578557 | 0.99 | DRD2 (0.98) | DRD2HTR2AHTR1AKCNH2HTR2C | |
| Risperidone SCHEMBL5774262 | 0.99 | DRD2 (0.98) | DRD2HTR2AHTR1AKCNH2HTR2C | |
| Risperidone SCHEMBL28382198 | 0.99 | DRD2 (0.98) | DRD2HTR2AHTR1AKCNH2HTR2C | |
| Risperidone SCHEMBL29051431 | 0.96 | DRD2 (0.92) | DRD2HTR2AHTR1AKCNH2HTR2C | |
| Risperidone SCHEMBL3623879 | 0.96 | HTR2A (0.92) | DRD2HTR2AHTR1AKCNH2HTR2C | |
| SCHEMBL23696626 | 0.96 | DRD2 (0.92) | DRD2HTR2AHTR1AKCNH2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024146576-A1 | TRANSDERMAL ADMINISTRATION SYSTEM FOR RISPERIDONE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 新领医药技术(深圳)有限公司 | 2024-07-11 | — | — | WO | disclosed |
| WO-2024127024-A1 | CANNABINOID BASED THERAPY | Kingdom Therapeutics Limited (GB) | 2024-06-20 | — | — | WO | disclosed |
| US-10927138-B2 | Inhibitors of D-amino acid oxidase (DAAO) and uses thereof | SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) | 2021-02-23 | — | — | US | disclosed |
| CN-109602692-A | Injectable control release composition comprising high viscosity liquid carrier | 度瑞公司 | 2019-04-12 | — | — | CN | disclosed |
| CN-105163719-B | Injectable controlled release compositions comprising high viscosity liquid carriers | 度瑞公司 | 2019-03-08 | — | — | CN | disclosed |
| WO-2017139487-A1 | METHODS, AGENTS, AND DEVICES FOR LOCAL NEUROMODULATION OF AUTONOMIC NERVES | NORTHWIND MEDICAL, INC. (US) | 2017-08-17 | — | — | WO | disclosed |
| EP-2906208-A1 | THERAPEUTIC TREATMENT | Sears, Douglas (US) | 2015-08-19 | — | — | EP | disclosed |
| EP-2815236-A1 | MEANS AND METHODS FOR ASSESSING AN ENDOCRINE DISEASE OR DISORDER | BASF SE (DE) | 2014-12-24 | — | — | EP | disclosed |
| WO-2013121380-A1 | MEANS AND METHODS FOR ASSESSING AN ENDOCRINE DISEASE OR DISORDER | BASF SE (DE) | 2013-08-22 | — | — | WO | disclosed |
| US-20130144250-A1 | IMPLANTABLE DRUG DELIVERY COMPOSITIONS AND METHODS OF TREATMENT THEREOF | ENDO PHARMACEUTICALS SOLUTIONS INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-8420624-B2 | Methods for treating or preventing symptoms of hormonal variations | YUNG SHIN PHARM. IND. CO., LTD. (TW) | 2013-04-16 | — | — | US | disclosed |
| EP-1758600-A4 | METHODS AND COMPOSITIONS FOR TREATING MOOD DISORDER | MOOD MAN SCIENCES LLC (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2007093870-A2 | A PROCESS FOR THE PREPARATION OF RISPERIDONE | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2007-08-23 | — | — | WO | disclosed |
| CN-1988896-A | Use of compounds active on the sigma receptor for the treatment of mechanical allodynia | ESTEVE LABOR DR (ES) | 2007-06-27 | — | — | CN | disclosed |
| EP-1758600-A1 | METHODS AND COMPOSITIONS FOR TREATING MOOD DISORDER | Mood Management Sciences, LLC (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005120523-A1 | METHODS AND COMPOSITIONS FOR TREATING MOOD DISORDER | MOOD MANAGEMENT SCIENCES, LLC (US) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005013969-A1 | ANTIPSYCHOTIC AGENT WITH SOCIALIZING PROPERTIES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927138-B2 | Inhibitors of D-amino acid oxidase (DAAO) and uses thereof | DAO, DDO, DDC | DRD2 1624/4885HTR2A 1703/4885HTR2C 2544/4885 |
| US-20130144250-A1 | IMPLANTABLE DRUG DELIVERY COMPOSITIONS AND METHODS OF TREATMENT THEREOF | ESR1, CYP19A1, ESR2 | DRD2 256/4885HTR2A 651/4885HTR2C 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.